BIOG B Share Price Performance
SEK 101.00
-8.60 (-7.85%)
22.3% undervalued intrinsic discount
SEK 130.00
Fair Value
Price SEK 101.00
AnalystConsensusTarget SEK 130.00
Fair ValueSEK 130.00
Share Pricen/a
BioGaia AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
BIOG B Community Narratives
AN
Fair Value SEK 130 22.3% undervalued intrinsic discount
Expanding North American Demand Will Unlock New Health Trends
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
Expanding North American Demand Will Unlock New Health Trends
Key Takeaways Expansion in direct sales and mainstream retail channels supports sustained growth as preventative health trends and demand for natural, clinically-proven products intensify globally. Increased investment in innovation, marketing, and clinical research is expected to drive margin expansion and diversification despite short-term earnings pressure.Read more
76
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
SEK 130
22.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
11.49% p.a.
Profit Margin
28.17%
Future PE
26.98x
Price in 2028
SEK 149.9
Trending Discussion
Recently Updated Narratives
AN
Expanding North American Demand Will Unlock New Health Trends
Fair Value: SEK 130 22.3% undervalued intrinsic discount
9 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Flawless balance sheet with high growth potential and pays a dividend.
1 Risk
2 Rewards
BioGaia AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 12, 2026
- 3.12
- 72.71%
- 21.60%
- 0%
About BIOG B
- Founded
- 1990
- Employees
- 238
- CEO
- WebsiteView website
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablets and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee’s dairy product. The Other segment provides packaging solutions. It sells its products through distribution partners or through its own distribution channels. BioGaia AB (publ) was incorporated in 1990 and is based in Stockholm, Sweden.
